A detailed history of Nebula Research & Development LLC transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Nebula Research & Development LLC holds 20,360 shares of XENE stock, worth $733,367. This represents 0.09% of its overall portfolio holdings.

Number of Shares
20,360
Previous 24,265 16.09%
Holding current value
$733,367
Previous $955 Million 16.46%
% of portfolio
0.09%
Previous 0.11%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$38.14 - $45.74 $148,936 - $178,614
-3,905 Reduced 16.09%
20,360 $798 Million
Q3 2024

Nov 14, 2024

SELL
$36.12 - $43.96 $214,227 - $260,726
-5,931 Reduced 19.64%
24,265 $955 Million
Q2 2024

Aug 14, 2024

BUY
$36.25 - $43.75 $1.09 Million - $1.32 Million
30,196 New
30,196 $1.18 Billion
Q4 2023

Feb 14, 2024

BUY
$28.7 - $46.46 $208,964 - $338,275
7,281 New
7,281 $335 Million

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.24B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Nebula Research & Development LLC Portfolio

Follow Nebula Research & Development LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nebula Research & Development LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nebula Research & Development LLC with notifications on news.